{"id":"W4386959308","doi":"10.1016/j.jtct.2023.09.014","title":"Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial","year":2023,"lang":"en","type":"article","venue":"Transplantation and Cellular Therapy","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network; Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; National Institutes of Health; Takeda Pharmaceuticals U.S.A.; Bristol-Myers Squibb; Multiple Myeloma Research Foundation","keywords":"Medicine; Pomalidomide; Multiple myeloma; Maintenance therapy; Dexamethasone; Salvage therapy; Internal medicine; Melphalan; Transplantation; Autologous stem-cell transplantation; Surgery; Progression-free survival; Oncology; Lenalidomide; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004052477,0.0002130125,0.0004551592,0.0001881585,0.0001307897,0.00002488874,0.00004590807,0.0001093311,0.0000146521],"category_scores_gemma":[0.00005935611,0.000174448,0.0001467479,0.0001800822,0.00009670135,0.0001171417,0.000003525362,0.0001066578,0.000003104521],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002664122,"about_ca_system_score_gemma":0.0000497804,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007174075,"about_ca_topic_score_gemma":0.0000592087,"domain_scores_codex":[0.998485,0.0001004309,0.0004435251,0.0004063756,0.0002344623,0.0003302253],"domain_scores_gemma":[0.9990057,0.0004919429,0.0001255439,0.000136833,0.00009461474,0.0001454062],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6259248,0.0008402424,0.007386867,0.0008154629,0.0008154404,0.0007314847,0.008077582,0.000004211018,0.3060138,0.00009109802,0.00004395007,0.04925504],"study_design_scores_gemma":[0.6660466,0.004235576,0.04637934,0.0002147077,0.0002895692,0.00007492648,0.0005354772,0.003474131,0.278002,0.0001049673,0.000395846,0.0002469237],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919061,0.0004495133,0.003213666,0.0001501409,0.0001002704,0.003331997,0.000601411,0.00009016796,0.0001567043],"genre_scores_gemma":[0.9946147,0.002100031,0.001381564,0.00005024848,0.00003987513,0.0002907295,0.001043967,0.00003201634,0.00044683],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04900811,"threshold_uncertainty_score":0.7113781,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02814743779167149,"score_gpt":0.3177173585751594,"score_spread":0.2895699207834879,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}